Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

Recruiting now

Conditions studied: Pancreatic Adenocarcinoma, Weight Loss

In brief

The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.

Key facts

Study ID

NCT06988150

Run by

Cedars-Sinai Medical Center

People needed

100

Starts

2025-04-14

Expected to finish

2026-04-14

Last updated by the study team

2025-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men, Women, and all genders
• Individuals 18 years old or older are included.
• Patients of the study investigators and team members
• Diagnosis of pancreatic ductal adenocarcinoma
• All subjects must consent to this study
• Clinically diagnosed weight loss

You may not qualify if…

• Minors
• Pregnant Women
• Any records flagged "break the glass" or "research opt out."
• Patients who have received treatment for SIBO in the past 3 months

Where it is running

• Cedars-Sinai Medical Center — Los Angeles, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.